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Recanalization of acute large artery occlusions is a strong predictor of good outcome. The
development of thrombectomy devices resulted in a signiﬁcant improvement in recanal-
ization rates compared to thrombolytics alone. However, clinical trials and registries with
these thrombectomy devices in acute ischemic stroke (AIS) have shown recanalization
rates in the range of 40–81%.The last decade has seen the development of nickel titanium
self-expandable stents (SES). These stents, in contrast to balloon-mounted stents, allow
better navigability and deployment in tortuous vessels and therefore are optimal for the
cerebral circulation. SES were initially used for stent-assisted coil embolization of intracra-
nial aneurysms and for treatment of intracranial stenosis. However, a few authors have
recently reported feasibility of deployment of SES in AIS.The use of these devices yielded
higher recanalization rates compared to traditional thrombectomy devices. Encouraged by
these results, retrievable SES systems have been recently used in AIS.These devices offer
the advantage of resheathing and retrieving of the stent even after full deployment. Someof
these stents can also be detached in case permanent stent placement is needed. Retriev-
able SES are being used in Europe and currently tested in clinical trials in the United States.
We review the recent literature in the use of stents for the treatment of AIS secondary to
large vessel occlusion.
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INTRODUCTION
Recanalization is a strong predictor of good outcome in cere-
bral ischemia secondary to large vessel occlusion (Nogueira et al.,
2009a). Recanalization rates with Food and Drug Administration
(FDA) approved thrombectomy devices such as the Concentric
Thrombus Retriever (Concentric Medical, Mountain View, CA,
USA) and the Penumbra System (Penumbra Inc., Alameda, CA,
USA) range between 40 and 81% (Flint et al., 2007).
In particular,pooled results of themechanical embolus removal
in cerebral ischemia (MERCI) and Multi MERCI Part I trials
showed a 63% recanalization rate with the use of the Merci
Retriever and adjunctive endovascular treatment (Flint et al.,
2007).Good clinical outcomes (ModiﬁedRankinScale,mRS≤ 2 at
3months) were observed in 39%patients with ICA recanalization.
Theother FDAapproveddevice formechanical thrombectomy, the
Penumbra System, showed an 81% recanalization rate (thrombol-
ysis in myocardial infarction, TIMI 2/3; Penumbra Pivotal Stroke
Trial Investigators, 2009). Good clinical outcome (mRS≤ 2 at
3months) was seen in 25% of patients. Unfortunately, recanal-
ization rates with these devices are variable and some lesions like
carotid terminus or basilar artery occlusions have a poor response
to alternative therapies like thrombolytics (IMS Study Investi-
gators, 2004). Furthermore, the Merci Retriever often requires
frequent passes to achieve complete recanalization (Smith et al.,
2005); while the Penumbra aspiration system generates clot frag-
ments that may embolize distally (Gounis et al., 2010). Newer
and better endovascular devices are needed to achieve better
outcomes.
Balloon-mounted stents and later on, self-expandable stents
(SES),have beenusedwith increased success in large vessel recanal-
ization during acute ischemic stroke (AIS). Moreover, retrievable
SES systems like the Solitaire (ev3, Plymouth, MN, USA) and
Trevo (Concentric Medical, Mountain View, CA, USA) offer the
advantage of stent resheathing even after full deployment and
detachment of the stent in cases where permanent stent placement
is needed (Solitaire FB). In this review we analyze the evolution of
stent technology for treatment of AIS.
HISTORICAL PERSPECTIVE
Phatouros et al. (1999) reported the ﬁrst endovascular stent-
ing of an acutely occluded basilar artery with excellent angio-
graphic results. In their case report, after failure to recanalize the
occluded vessel with intraarterial (IA) thrombolysis and balloon
angioplasty, a balloon-mounted stent was successfully deployed
resulting in TIMI-3 ﬂow. Gupta et al. (2003) reported a series
of 18 patients treated urgently with angioplasty and/or stenting
due to impending stroke. Four patients in this series under-
went stenting, although only two had acute strokes in diffusion
weighted imaging. The overall rate of major periprocedural com-
plications was 50%. Levy et al. (2006a) treated 19 patients with
AIS and achieved TIMI 2/3 in 79% of cases. All the patients
in this series failed different recanalization approaches, which
included angioplasty, IA thrombolysis, and thrombectomy with
a snare device. The rate of intracerebral hemorrhage was 5%. All
the stents used up to this point are coronary balloon-mounted
stents.
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SELF-EXPANDABLE INTRACRANIAL STENTS
Self-expandable stents were approved for vessel remodeling in the
treatment of cerebral aneurysms and intracranial atherosclerotic
disease. The Enterprise stent (Cordis Neurovascular,Miami Lakes,
FL, USA), the Neuroform system (Stryker, Natick,MA, USA), and
the Leo stent (Balt Extrusion, Montmorency, France) are devices
introduced for stent-assisted coiling of wide-neck aneurysms. The
latter stent is not marketed in the United States. The Wingspan
system (Stryker, Natick, MA, USA) was approved for treatment of
intracranial atherosclerosis. Both the Neuroform and Wingspan
stents have an open-cell design, whereas the Enterprise and Leo
stents are closed-cell design (Nogueira et al., 2009b). The closed-
cell design allows resheathing of the stent after partial deployment
(70% for Enterprise and 90% for Leo; Lubicz et al., 2006; Peluso
et al., 2008).
These devices have been used off-label in the treatment of
AIS. The concept of ﬂow restoration without clot removal has
gained attention as other recanalization approaches that focus
their strategy in thrombectomy have failed.
Fitzsimmons and Nelson reported one of the ﬁrst cases of
cerebral revascularization with deployment of a SES (Fitzsim-
mons et al., 2006). A Neuroform stent was deployed in an
occluded left middle cerebral artery after the IA infusion of
a glycoprotein (GP) IIb/IIIa inhibitor failed to recanalize the
vessel. Multiple reports have followed (Table 1), especially
from the group lead by Levy et al. (2007a) who have pio-
neered the use of SES in the treatment of AIS. In 2007 they
reported a 100% successful deployment of SES (16 Neuro-
form and 3 Wingspan stents) in the target occlusion, achiev-
ing a thrombolysis-in-cerebral-infarction score (TICI)/TIMI 2/3
recanalization in 79% of lesions. Four patients (22%) had
a modiﬁed Rankin Scale (mRS)≤ 3 at 3months and two
patients (11%) suffered symptomatic intracerebral hemorrhage
(sICH).
Most of the studies published to date have been retrospective
single-center reports with sample sizes ranging between 9 and 20
patients (Zaidat et al., 2008; Brekenfeld et al., 2009; Mocco et al.,
2010; Suh et al., 2010; Linfante et al., 2011).Although these cohorts
are small, recanalization rates of 92 and 100% have been reported
in cases where other thrombectomy devices have failed (Breken-
feld et al., 2009; Mocco et al., 2010; Linfante et al., 2011). The
stent-assisted recanalization in AIS (SARIS) study, is a prospec-
tive trial that recently reported preliminary data in the treatment
of 20 patients with AIS. TIMI 2/3 was achieved in 100% of cases
with a 5% rate of sICH (Levy et al., 2009). A 6-month follow-
up of the SARIS trial found mRS≤ 2 in 55% of patients (n = 11)
with a mortality rate of 35% (n = 7). None of the patients had in-
stent restenosis and all had TIMI-3 ﬂow in angiographic follow-up
(Levy et al., 2011).
We recently reported our experience in the use of SES for
treatment of AIS refractory to other recanalization treatments
(Linfante et al., 2011).We reviewed our database of stroke patients
treated between August 2008 and September 2010. A total of 19
patients with AIS underwent stenting achieving a 95% recanal-
ization rate (Figures 1–3). 42% of patients achieved a mRS≤ 2.
We did not experience any technical complications, however, due
to the routine IA administration of GP IIb/IIIa inhibitors before
stent deployment we encountered a higher rate of sICH (16%).
16 patients in our series received concomitant administration of
intravenous (IV) and/or IA tissue plasminogen activator (tPA).
















Levy et al. (2007a) 18 16 (N), 3 (W) 79 (TICI/TIMI 2/3) GP 10 (56) 5 (28) 2 (11) 22 (mRS≤3 at 3M)
Zaidat et al. (2008) 9 4 (N), 5 (W) 89 (TICI/TIMI 2/3) GP 6 (67) 1 (11) None 67 (mRS≤2 at mean
follow-up 12.5M)
Brekenfeld et al. (2009) 12 14 (W) 92 (TIMI 2/3) GP 1 (8) None None 35 (mRS≤2 at 3M)
Mocco et al. (2010) 20 20 (E) 100 (TIMI 2/3) GP 11 (55) 10 (50) 2 (10) 75 (NIHSS ↓≥4)
Linfante et al. (2011) 19 13 (W), 6 (E) 95 (TIMI 2/3) GP 19 (100) 8 (42) 3 (16) 42 (mRS≤2 at 1M),
63 (mRS≤3 at 1M)




Roth et al. (2010) 22 22 (S) 91 (TICI 2a/b/3) IV ASA 6 (27)* 13 (59) 2 (9) 50 (mRS≤2 at 3M)
Castano et al. (2010) 20 20 (S) 90 (TICI 2/3) None 10 (50) 2 (10) 45 (mRS≤2 at 3M)
Machi et al. (2011) 56 56 (S) 89 (TICI 2b/3) None NA 1 (1.8) 46 (mRS≤2 at
discharge)
Mpotsaris et al. (2011) 26 26 (S) 88 (TIMI 2/3) None 19 (73) NA 38 (mRS≤2 at
discharge)
+SARIS is the only single-arm prospective study of primary stenting in stroke approved by the Food and Drug Administration.
∗Intravenous aspirin was administered in six patients with tandem internal carotid artery occlusions/stenosis whom required stenting.
N, neuroform stent; W, wingspan stent; E, enterprise stent; S, solitaire stent; IV, intravenous; tPA, tissue plasminogen activator; sICH, symptomatic intracerebral
hemorrhage; TICI, thrombolysis in cerebral infarction; TIMI, thrombolysis in myocardial infarction; M, month; GP, glycoprotein IIb/IIIa inhibitors; ASA, acetyl salicylic
acid; NA, not available; mRS, Modiﬁed Rankin Scale; NIHSS, National Institute of Health Stroke Scale; SARIS, stent-assisted recanalization for acute ischemic stroke;
SES, self-expandable stents.
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FIGURE 1 | Computed tomography perfusion (CTP) of a 53-year-old
man who presented with a National Institute of Health Stroke Scale of
20 approximately 2h after symptom onset.The perfusion map
demonstrates a mismatch with increased mean transient time (A) and
normal blood volume (B) in the left middle cerebral artery (MCA) territory.
FIGURE 2 | Cerebral angiogram shows a left MCA-M1 occlusion (A),
which was successfully recanalized with deployment of a
self-expandable stent (B). Intraarterial infusion of tissue plasminogen
activator (25MG) and thrombectomy with the Concentric Merci Retriever
failed to recanalize the occlusion. Arrows demonstrate the proximal and
distal ends of the stent.
The cumulative experience of these reports has let to the
following observations:
1. Stenting in AIS appears to be technically feasible as reported
in the 100% successful deployment rate of different studies
(Brekenfeld et al., 2007; Levy et al., 2007a, 2009; Mocco et al.,
2010; Linfante et al., 2011). Zaidat et al. (2008) reported one
technical failure when aWingspan stent could not track beyond
FIGURE 3 | Computed tomography (CT) angiography demonstrating
patency of the stent in a 6-month follow-up (A). Non-contrast CT
demonstrates a small left MCA territory infarct (B).
the middle cerebral artery/internal carotid artery junction and
was deployed in the proximal clot.
2. Acute in-stent thrombosis is rare and different treatment strate-
gies may be used to achieve stent recanalization: IA adminis-
tration of GP IIb/IIIa inhibitors (Zaidat et al., 2008; Brekenfeld
et al., 2009; Suh et al., 2010), angioplasty (Zaidat et al., 2008),
and stent resheathing (the Enterprise system allows recapture
after partial deployment; Suh et al., 2010).
3. Enterprise stents appear to have better navigability than the
Wingspan and Neuroform stents, especially in AIS patients
who generally have a tortuous anatomy with atherosclerotic
changes. Levy et al. (2009) used Enterprise stents in two cases
where the Wingspan system could not be advanced due to
severe vessel tortuosity. In our experience, Enterprise stents
were successfully deployed in two cases where cerebrovascu-
lature tortuosity limited the use of Wingspan (Linfante et al.,
2011). Moreover, we were able to deploy an Enterprise stent
in a right M1 occlusion through the contralateral left internal
carotid artery and across the anterior communicating artery
due to occlusion of the proximal right common carotid artery.
The Enterprise catheter-based delivery system appears to have
improved navigability and ease of deployment as Mocco et al.
(2010) reported as well in their cohort of 20 patients with
AIS.
4. Despite concerns that SES would not have the enough radial
force to recanalize occluded arteries, angiographic outcomes
have improved since the ﬁrst series published by Levy et al.
(2009) achieving TIMI 2/3 ﬂow in more than 90% of lesions
(Brekenfeld et al., 2009; Levy et al., 2009; Mocco et al., 2010;
Linfante et al., 2011).
5. Antiplatelet agents such as aspirin and clopidogrel or GP
IIb/IIIa inhibitors should be administered prior to stent deploy-
ment to avoid acute in-stent thrombosis (Zaidat et al., 2008;
Brekenfeld et al., 2009; Suh et al., 2010). However, this may
lead to sICH if thrombolytic agents have been previously
administered (Linfante et al., 2011).
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In summary, SES like the Enterprise, Neuroform, and Wingspan
systems appear to have better navigability, trigger less vasospasm,
and side-branch occlusions than balloon-mounted stents (Levy
et al., 2006b). Additionally, SES do not require balloon inﬂation in
vessels with an unknown diameter. Unfortunately, SES can only be
used in ≥2-mm vessels and chemical thrombolysis may be needed
to achieve complete distal recanalization, increasing the risk of
sICH.
A large multicenter retrospective study that included 1122
patients with AIS determined that patients treated with mul-
timodal therapy had signiﬁcant higher TIMI 2/3 recanaliza-
tion rates (74%) compared with pharmacological therapy only
(61%) or mechanical treatment alone (63%; Gupta et al., 2011).
Among individual treatment modalities, stent deployment or IA
thrombolysis increased the chance of recanalization.
DRAWBACKS OF STENTS IN AIS
The use of SES in the AIS has potential drawbacks:
1. Permanent deployment of SES in the setting of AIS requires
platelet inhibition to reduce the possibility of in-stent throm-
bosis. Intra-procedural administration of GP IIb/IIIa inhibitors
or inhibitors of platelet function inAISmay in turn increase the
risk of hemorrhagic transformation. This is particularly worri-
some in patient who have already been treated with IV and/or
IA thrombolytics (Linfante et al., 2011).
2. Stent placement in AIS is a permanent implant to resolve a
temporary occlusion that may be caused by an embolus.
3. Stent deployment may result in delayed in-stent stenosis (Levy
et al., 2007b).
To eliminate these potential pitfalls, retrievable stents, also known
as “stentrievers,” were introduced. A stentriever can act as a stent
and recanalize the occluded lumen. It can then be retrieved so that
it does not become a permanent implant. While retrieved, it can
function as thrombectomy device as well.
RETRIEVABLE-THROMBECTOMY STENTS
Mayer et al. (2002) reported their experience in the treatment of
AIS with a self-expandable basket that had a stent conﬁguration
and was used to recanalize a basilar artery. The device, named
Neuronet (Guidant, Menlo Park, CA, USA), probably constitutes
an earlier version of a retrievable stent. Unfortunately, the device
was not commercialized.
In vitro and animal testing with the Enterprise stent showed
successful thrombectomy once the stent was resheathed after par-
tial deployment (Wakhloo and Gounis, 2008). Kelly et al. (2008)
reported successful recanalization of a right M1 occlusion with
an Enterprise stent after failed IA thrombolysis. The stent was
deployed for 20min and then reconstrained and removed. This
report is the ﬁrst account of a SES thatwas retrieved after achieving
recanalization in AIS. Hauck et al. (2009) used the same approach
for recanalization of a vertebrobasilar occlusion. A 4.5-mm× 37-
mmEnterprise stent was deployed for 18min and then recaptured
achieving a good angiographic result.
The Solitaire revascularizationdevice is a stent based thrombec-
tomy system with a closed-cell design speciﬁcally designed to
operate as a “retrievable” stent. The device has a dual purpose:
temporal intracranial bypass with ﬂow restoration through the
occluded arterial segment; and clot retriever after trapping the
thrombus into its cells. Current reports with this device come
from different European centers since the device is not currently
approved in the United States. Castano et al. (2010) reported their
experience in the treatment of 20 patients with AIS and large ves-
sel occlusion in the anterior circulation. TICI 2b/3 was achieved
in 90% of treated vessels and no procedural complications were
reported. sICH occurred in 10% of patients and 45% achieved a
mRS≤ 2 at 3months. The device used in this study is the Solitaire
AB stent, initially designed as an aneurysm neck bridging stent.
The device was deployed for 1 or 2min before retrieving it to per-
form embolectomy. Recanalization required in average 1.4 passes.
The successful off-label use of this stent prompted the creation of
the Solitaire FR device with minimal modiﬁcations from the AB
version, and speciﬁcally designed for treatment of AIS.
Machi et al. (2011) achieved successful recanalization in 50 out
of 56 patients (89%) treated with the Solitaire FR device . Proce-
dure related complications occurred in 9% of patients and 46%
achieved a mRS≤ 2 at discharge. The mean number of passes
required per procedure was 2 (1–5 range). The device was posi-
tioned across the area of occlusion for 3–7min and then gently
recovered into the guide catheter. Vasospasm during retrieval of
the fully deployed stent was a common phenomenon, two patients
had asymptomatic SAH and one patient sICH.
Similarly, Roth et al. (2010) treated 22 patients with AIS and
achieved TICI 2a/b and 3 ﬂow in 91% of patients. Two sICH
occurred and 50% of patients achieved a mRS≤ 2 at 90 days.
Vasospasm after thrombectomy was noticed in three patients and
no device-related complications were reported.
Investigators of the rescue, combined, and stand-alone
thrombectomy (RECOST) study, achieved TICI 3 ﬂow in 84% of
patients with AIS treated with the Solitaire FR/AB device (Costalat
et al., 2011). The aim of this study was to evaluate and appraise
the timing, safety and efﬁcacy of an integrated strokemanagement
protocol. At 3months, 54% of patients achieved a mRS≤ 2 and
2% had sICH. The device was deployed for 2–7min in the target
occlusion before thrombectomy.
The Trevo System is a non-deployable stent-like device cur-
rently being used in Europe and Canada. The soft body of the
device allows easy navigation through tortuous vessels and its
distal closed-end is intended to prevent vessel perforation. The
device can be used in vessels ranging from 1.5 to 3.5mm in diam-
eter. The orientation of the stent struts has the broader portion
of the struts facing the vessel lumen in order to optimized throm-
bus incorporation, opposite to the design of stents used to treat
intracranial aneurysms of intracranial atherosclerosis (Nogueira
et al., 2011).
These results appear promising as the devices continue to
evolve, become more operator friendly and patient outcomes
improve. Three studies are underway in the United States and
Europe to test retrievable stents in the treatment of AIS. The
Solitaire FR with the Intention for Thrombectomy (SWIFT)
study which is ongoing (recruitment completed) and will com-
pare Solitaire FR with the Merci retriever in 200 patients. The
Trial and Cost Effectiveness Evaluation of IA Thrombectomy
in AIS (THRACE) study will compare IV thrombolysis with
thrombectomy procedures using the Merci retriever, Penumbra
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system, Catch device (Balt Extrusion, Montmorency, France),
and the Solitaire FB stent in 480 patients. The Thrombectomy
Revascularization of Large Vessel Occlusions (TREVO 2) study
was recently started in the United States and will compare
the Trevo system versus the Merci retriever in the treatment
of AIS. Approximately 178 patients would be enrolled in the
study.
TECHNICAL BENEFITS AND LIMITATIONS OF STENTING
IN AIS
Deployment of the stent at the occlusion site with ﬂow restora-
tion to the area at risk may increase tissue savage. Experimental
research in animal models has shown that intermittent restoration
of ﬂow to the infarct area can reduce the ﬁnal infarct size (Zhao,
2009). The stent bypasses the area of occlusion restoring ﬂow to
more distal branches.
Once the stent is open, the clot gets trapped between
the stent and the vessel wall. This is an important concept
and differs from conventional thrombectomy approaches aimed
to extract the clot. This latter strategy is more laborious
and time consuming, delaying recanalization. Once the stent
expands through the occlusion, thrombus material may be
pushed into perforating arteries. This phenomenon described
as “snow-plowing,” (Levy and Chaturvedi, 2006) may explain
strokes in perforator territories once the main artery has been
recanalized and may be one of the drawbacks of this tech-
nique.
A technical aspect of thrombectomy with the retrievable stents
is the deployment time. It is advised to unsheathe the device for at
least 2min to allow full expansion of the nitinol struts through the
thrombus, this facilitates clot entrapment and later on thrombec-
tomy. Deployment times have varied between 1 and 7min among
different studies (Castano et al., 2010; Costalat et al., 2011; Machi
et al., 2011).
Withdrawing an unfolded stent to perform thrombectomy
increases the risk of intimal injury to the vessel wall. Preliminary
FIGURE 4 | Rapid evolvement of stroke therapies during the last 20 years.
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animal studies with the Solitaire device in swine were remark-
able for vasospasmwhich resolved without sequelae (Jahan, 2010).
Microscopic examination of the vessels were the device was
deployed showed mild intimal thickening leading to 1–5% nar-
rowing, which was not visualized in angiography. Vasospasm
and SAH have been described in clinical studies after thrombec-
tomy with the Solitaire device (Roth et al., 2010; Machi
et al., 2011). Histopathological analysis of swine external carotid
branches after thrombectomy with the Trevo stent, showed
severe disruption of the intimae but there was no hemor-
rhage nor evidence of transmural dissection (Nogueira et al.,
2011).
A theoretical advantage of retrievable stents over other con-
ventional thrombectomy devices is that “stentrievers” gradually
expand as they are pulled proximally into the guide catheter.
Indeed, the inherent radial force of the stentriever theoreti-
cally traps the clot against the vessel wall during thrombec-
tomy. This may prevent the retrieved thrombi from dislodging
from the stentriever and embolizing distally (Nogueira et al.,
2011).
If a suboptimal angiographic result is achieved after thrombec-
tomy, the Solitaire device can be reposition and permanently
deployed as an stent (AB version). The system allows detach-
ment of the stent-like a coil. This application may be useful in
recanalization of atherothrombotic lesions or if the stent cannot
be recaptured.
CONCLUSION
Stents initially conceived for aneurysm remodeling (Enterprise
and Neuroform stents) and treatment of intracranial atheroscle-
rosis (Wingspan stent) have paved the way for new therapeutic
approaches in AIS (Figure 4). SES are easier to deliver than
balloon-mounted stents and are thought to carry a lower risk of
vascular injury (Chiam et al., 2008; Samaniego et al., 2009). How-
ever, these devices usually require loading doses of antiplatelet
medications before permanent stent deployment. Moreover, dual
antiplatelet therapy is continued for at least the initial 3months
after the procedure. This raises safety concerns in patients who
have received IV or IA thrombolytics. In our experience, routine
administration of IA GP IIb/IIIa inhibitors before stent deploy-
ment despite previous IV and/or IA tPA administration carries a
higher risk of sICH (Linfante et al., 2011).
Retrievable stents appear to ease this technical issue, once
deployed they bypass the area of occlusion providing ﬂow to the
ischemic area at risk. The operator may then recapture the stent
or perform a thrombectomy with the stent unsheathed. How-
ever, complications like vasospasm and intimal injury with vessel
rupture have been reported with this approach.
In summary, deployment of SES in AIS may be a safe alterna-
tive for recanalization of large intracranial vessels in patients in
whom other current available devices failed. Newer stent-based
technologies like retrievable stents may add evenmore tools to the
treatment of AIS.
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